MDXG MIMEDX GROUP, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1376339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.8%
TTM net income YoY-147.0%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR-0.6%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-8.3%
Net margin-6.3%
FCF margin—
EBITDA margin-3.5%
Returns
ROE-8.5%
ROA-6.6%
ROIC (approx.)-19.3%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets20.2%
Debt / equity0.00x
Current ratio4.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.08x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $418.63M | $348.88M | $321.48M | $267.84M | $242.02M |
| Cost of revenue | $73.01M | $60.07M | $54.63M | $48.32M | $39.63M |
| Gross profit | $345.62M | $288.81M | $266.84M | $219.53M | $202.39M |
| R&D expense | $15.10M | $12.34M | $12.66M | $12.70M | $9.93M |
| SG&A expense | $266.19M | $225.09M | $211.12M | $208.67M | $194.85M |
| Operating income | $63.89M | $58.87M | $37.12M | -$14.73M | -$7.05M |
| Interest expense | $1.78M | $3.94M | $6.58M | $5.05M | — |
| Pretax income | $66.26M | $57.29M | $30.63M | -$19.75M | -$12.05M |
| Income tax | $17.68M | $15.30M | -$36.81M | $206,000 | $247,000 |
| Net income | $48.58M | $42.42M | $58.23M | -$30.20M | -$10.29M |
| EBITDA | $78.77M | $64.91M | $40.54M | -$11.38M | -$2.69M |
| EPS (basic) | 0.33 | 0.29 | 0.40 | -0.33 | -0.15 |
| EPS (diluted) | 0.32 | 0.28 | 0.37 | -0.33 | -0.15 |
| Weighted avg. shares (diluted) | 149.72M | 149.05M | 145.96M | 112.91M | 110.35M |
| Banking | |||||
| Net interest income | — | — | -$6.46M | -$5.02M | -$4.98M |
| Balance sheet | |||||
| Cash & equivalents | $166.12M | $104.42M | $82.00M | $65.95M | $87.08M |
| Receivables | $75.71M | $55.83M | $53.87M | $43.08M | $40.35M |
| Inventory | $25.34M | $23.81M | $21.02M | $13.18M | $11.39M |
| Current assets | $277.47M | $191.89M | $164.26M | $134.20M | $148.52M |
| PP&E, net | $4.71M | $5.94M | $6.97M | $7.86M | $9.16M |
| Goodwill | $19.44M | $19.44M | $19.44M | $19.44M | $19.44M |
| Intangibles | $14.16M | $11.63M | $5.26M | $5.85M | $5.38M |
| Total assets | $342.65M | $263.92M | $239.05M | $171.43M | $187.93M |
| Current liabilities | $64.27M | $45.59M | $46.01M | $43.56M | $42.36M |
| Short-term debt | $1.50M | $1.00M | $1.00M | — | — |
| Long-term debt | $16.47M | $17.83M | $48.10M | $48.59M | $48.13M |
| Total debt | $17.97M | $18.83M | $49.10M | $48.59M | $48.13M |
| Total liabilities | $86.11M | $70.81M | $96.33M | $96.92M | $95.35M |
| Shareholders' equity | $256.55M | $193.11M | $142.72M | -$17.99M | $82,000 |
| Net debt | -$148.15M | -$85.59M | -$32.90M | -$17.36M | -$38.96M |
| Shares outstanding | 148.09M | 146.93M | 146.23M | 113.71M | 111.93M |
| Cash flow statement | |||||
| Operating cash flow | $74.00M | $66.20M | $26.77M | -$17.89M | -$1.98M |
| Capital expenditure | — | — | $1.99M | $1.51M | $3.22M |
| Free cash flow | — | — | $24.79M | -$19.41M | -$5.20M |
| Investing cash flow | -$6.89M | -$9.58M | -$2.15M | -$2.66M | -$3.40M |
| Financing cash flow | -$5.41M | -$34.20M | -$8.57M | -$580,000 | -$3.35M |
| Depreciation & amortization | $14.88M | $6.04M | $3.43M | $3.35M | $4.36M |
| Stock-based compensation | $16.40M | $16.93M | $16.96M | $11.33M | $14.16M |
| Share buybacks | $0 | $0 | $9.52M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.